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the late 1990s, the tenets of the “central dogma” have 
undergone revision as scientists began to appreciate 
that r n a s, by themselves, play key regulatory roles.
Leading the charge in this revolution are the 
small (18–25 nucleotide) non-coding r n a s called 
“small interfering” r n a s (sir n a s) and micro-r n a s 
(mir n a s), which direct r n a  interference (r n a i) 
phenomena. The sir n a s and mir n a s are newly 
discovered regulatory molecules that control a va-
riety of biologic processes, including development, 
metabolism, and aging 1–3. The mir n a s often bind 
to complementary sequences in the 3′ untranslated 
regions of target messenger r n a s (mr n a s) to repress 
target gene expression; the sir n a s can bind to any 
complementary sequence in a target mr n a . Impor-
tantly, functional roles have been demonstrated for 
mir n a s in cancer 4,5, and the potential exists to use 
similar molecules as cancer therapeutics.
The present review outlines the underlying 
rationales for considering small r n a  therapeutics. 
Although most of the attention has been given to the 
use of sir n a s to inhibit gene function, we provide a 
broader overview and include novel and emerging 
strategies that are instead based on mir n a s. We 
highlight the potential of each strategy for cancer 
treatment and summarize the challenges that need 
to be overcome to fully harness r n a i- and mir n a-
based therapies.
2.  THE MOLECULAR BASIS FOR siRNA- AND 
miRNA-MEDIATED SILENCING
The silencing mediated by r n a i and mir n a  is initi-
ated when the double-stranded r n a  (dsr n a )–specific 
type iii endonuclease, Dicer, “recognizes” a dsr n a  
substrate. Processing by Dicer and its accessory 
proteins yields 18- to 25-nucleotide heteroduplex 
small r n a s (either sir n a s or mir n a s, depending on 
their origin). The mir n a s are usually endogenously 
transcribed; the sir n a s often derive from exogenous 
sources such as viruses 6,7. One of the strands of the 
small r n a  duplex is selected, loaded into Argonaute 
proteins, and assembled into an effector complex 
such as the r n a -induced silencing complex (r i s c). 
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1.  INTRODUCTION
These are very interesting times in the field of gene 
regulation as it affects development and cancer. Since 
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The other strand is often cleaved or unwound and 
degraded 8,9. A key feature for the use of r n a i in 
therapy is that the r i s c  can be directly programmed 
by exogenous mature sir n a s or mir n a s. In effect, this 
programming bypasses cleavage by Dicer and the 
interferon response triggered by dsr n a s larger than 
30 bp in mammalian cells 10. Generally, when a sir n a  
fully pairs with a target mr n a , the result is rapid and 
specific cleavage, an activity named “slicer” 11.
In contrast to sir n a s, mir n a s normally originate 
from gene-encoded precursor transcripts that are 
processed into precursor mir n a s. Those precursors 
fold as hairpins and serve as Dicer substrates 12. 
Embedded within the r i s c, mature mir n a s pair only 
partially with their mr n a  targets, thereby directing 
translation inhibition or reducing the stability of 
their target 13.
The gene-targeting information is non-symmet-
rically encoded within mature sir n a s or mir n a s. The 
5′ portion of the mir n a  at positions 2–7 is thought 
to encode the most important determinant to direct 
base-pairing with mr n a  targets. This portion (called 
the “core,” “nucleus,” or “seed” sequence) is most 
commonly conserved; it defines paralogous and 
orthologous families of mir n a s 14. Structural stud-
ies show a tight coordination of this 5′ determinant 
within the Argonaute proteins 15. The 3′ part of the 
mir n a  or sir n a  is more amenable to chemical modi-
fications, some of which occur naturally.
3.  THE BIOLOGIC IMPLICATIONS OF miRNAS 
FOR CANCER
To evaluate the potential of small r n a s in cancer 
therapy, an appreciation of how extensively they are 
tied to the normal cell’s gene regulation networks is 
essential. In human cells, mir n a s are estimated to 
account for more than 1000 genes (approximately 
3% of the total estimated number of genes) and to 
exert direct negative regulative pressure on more than 
30% of the entire coding gene set 14,16. Accordingly, 
mir n a s are known to regulate genes implicated in 
a wide range of cellular functions in development 
and homeostasis 17. In Caenorhabditis elegans, for 
example, the first two known mir n a s—lin-4 and 
let-7—control timing of cell differentiation during 
development. In let-7 mutants, stem cells in the skin 
frequently fail to terminally differentiate, electing 
instead to divide again. Such cellular events are the 
defining hallmarks of cancer 18.
Because misregulation of genes that control 
cell proliferation and cell fate often contribute to 
cancer development, mir n a s are unsurprisingly 
also implicated in cancer biology. Early evidence 
in humans indicates that mir n a  loci are associated 
with chromosome sites that are often deleted or 
amplified 19, and whose expression is dramatically 
altered during the onset of cancer 20. Intense current 
research aims to precisely delineate the functions of 
mir n a s in transformation and tumour growth 21–23. 
In an increasing number of reports, mir n a s are now 
being shown to be capable of acting as bona fide 
tumour suppressors or oncogenes, bringing about a 
major shift in the landscape of cancer research 24.
4.  siRNA- AND miRNA-BASED THERAPEUTIC 
STRATEGIES
The chemical properties of the various mir n a s vary 
little, and yet, through the sequences that they encode, 
they direct completely distinct activities. At least 
three distinct overall strategies were adopted early 
on for sir n a - and mir n a -based therapies. Each one 
aims (reasonably) to exploit the sequence-directed 
properties of the small r n a s:
First,  •  de novo reprogramming of the r n a i ma-
chinery can be utilized against a gene that has 
deleterious effects (Figure 1, panel 1).
Second, a physiologic mi •  r n a –mr n a  pair could 
be reproduced by programming the r i s c  using a 
known, beneficial mir n a —for example, a tumour 
suppressor mir n a  (Figure 1, panel 2).
Third, a nonhydrolyzable mimic of an  •  r n a  target 
could be generated to effectively sequester delete-
rious mir n a s from their pro-oncogenic functions 
(Figure 1, panel 3).
4.1    Harnessing RNAi: De Novo Programming with 
siRNAs
Perhaps the simplest and the most direct therapeutic 
strategy involving r n a i is to harness and redirect its 
machinery against a detrimental mr n a  target. It there-
fore comes as no surprise that this strategy is by far the 
most advanced in clinical trials. The sir n a -directed 
targeting of genes is currently being developed as a 
potential therapy in a great number of diseases 25,26. 
The keys to this strategy are identification of a func-
tional and effective r n a i target and optimization of 
the targeting process. The strategy can include, but is 
not limited to, knowing the uniqueness of the sir n a ’s 
target sequence in the genome, optimizing its loading 
into the r i s c , obtaining a measure of the accessibility 
of the sir n a  target site (structure, protein–r n a  interac-
tions), and possibly even adding tolerated covalent 
modifications to the sir n a . In addition, and common 
to each r n a i- or mir n a -based therapy, is the need to 
deliver the r n a  molecule or analog to the correct tissue 
and mr n a  target (see the “Challenges” subsection).
Many sir n a -based therapies are under develop-
ment, but surprisingly few are directed at oncogenic 
targets. Among the cancer-directed approaches is the 
targeting of pleiotrophin, which effectively reduced 
tumour growth in mouse xenograft models of glioblas-
toma multiforme 27. Another initiative of interest is the 
successful targeting of the Ews–Fli1 fusion oncoprotein 
in mouse models of metastatic Ewing sarcoma 28.RNAi AND miRNA-ORIENTED THERAPY
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4.2  Tilting the Balance: miRNAs As Drugs
A second potential approach in r n a i-based cancer 
therapy is to deliver a mature or engineered mir n a  
precursor to specific biologic compartments to affect 
its known and physiologic mr n a  targets. In effect, this 
strategy aims at the restoration, the strengthening, 
or the ectopic rewiring of known mir n a -target cir-
cuitry 29,30. In contrast with the de novo programming 
approach, this strategy relies heavily on prior and 
extensive characterization of the biologic functions 
of the mir n a  of interest. The idea would be
to know the identity of the physiologic targets of  • 
the mir n a  of interest, and
to have a good idea of how the associated genes  • 
are embedded within their genetic network.
This second aspect is important, considering that 
mir n a s often function as parts of loops (feedback and 
feed-forward) between gene networks. (For examples, 
see Li et al. 31 and Xu et al. 32)
One mir n a  that fits each of these requirements is 
let-7. Overexpression of let-7 in a mouse model of lung 
cancer involving an activated K-ras allele suppresses 
activating oncogenic ras mutations just as such 
overexpression does in C. elegans 33,34. Signalling 
by ras plays an important role in radioresistance, and 
radiotherapy is one of the three primary modalities 
used in combatting cancer. However, many cancers, 
including lung cancer, are radioresistant. Because 
let-7 represses ras, let-7 overexpression has been 
proposed to be a possible cause of radiosensitivity, a 
hypothesis that indeed proved to be the case in both 
lung cancer cells and in an in vivo C. elegans model 29. 
These data provided the first evidence that mir n a s 
could potentially augment current cancer therapies.
An even more recent publication reported the use 
of a similar strategy—named “mir n a  replacement 
therapy”—aimed at restoring mir26a expression in 
hepatocellular carcinoma. When delivered in a mouse 
model using adeno-associated virus, this mir n a  was 
able to suppress proliferation and induce apoptosis, 
which resulted in inhibition of hepatocellular carci-
noma progression 35.
4.3    Sequence-Directed Inhibition: miRNAs As Drug 
Targets
Where the strategies already discussed are based on 
programming of the r i s c , a third promising strategy 
involves inhibition of the endogenous functions of 
well-characterized mir n a s. This inhibition is ac-
complished by “base-pairing”: using complementary 
nucleic acid analogs to block the unique signature of 
small r n a s (mainly the “seed”). One major advantage 
of this strategy is that the constraints required to con-
tact or base-pair with a mir n a  sequence are likely to 
be much looser than the requirements to fit within 
the tightly coordinated binding pocket of the r i s c  and 
to act as a functional r n a i component. These looser 
constraints in turn allow for greater chemical and 
covalent modifications to be made to the backbone of 
the analog inhibitor to change its stability, mir n a -in-
hibiting properties, and even its pharmacokinetics and 
biodistribution. At this stage, the frontrunners of these 
modifications are the locked nucleic acids (l n a s) 36 
2′-O-methyl 37,38 and 2′-O-methoxyethyl 39,40. In ad-
dition to combinations of these modifications, analogs 
such as the “antagomirs” (mirs) are modified with 
phosphorothioate substitutions on the backbone and 
with cholesterol conjugation 36.
A recent and successful example of this overall 
strategy is the in vivo inhibition of mir122 mir n a  
using a 15-nucleotide l n a-bearing analog 41. The 
liver-specific mir122 has been implicated in cho-
lesterol and lipid metabolism and has been linked 
to replication of hepatitis C virus (h c v) in vitro 42. 
A recent study by Elmen and colleagues is the first 
to report inhibition of mir n a s by analogs in vivo in 
nonhuman primates. Reduction of mature mir122 
levels in the liver was accompanied by a substan-
tial and reversible reduction in plasma cholesterol, 
f i g u r e  1  Therapeutic strategies based on “small interfering” 
r n as (sir n as) and micro-r n as (mir n as). r i s C = r n a-induced silencing 
complex; a g O  = Argonaute protein; mr n a = messenger r n a.DUCHAINE and SLACK
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without inducing any detectable sign of toxicity or 
tissue damage 41. This work raised the possibility that 
mir122 could be targeted in chronically infected h c v  
patients, for example, which could in turn reduce the 
associated risk of carcinoma. In a broader sense, this 
work highlights the potential of targeting mir n a s 
using l n a  analogs in therapy, with low toxicity and 
high specificity.
Although the use of mir n a  inhibitors is only start-
ing to emerge as a therapeutic strategy, an important 
number of studies have reported mir n a  targeting by 
analogs in cell culture or mouse models. Successfully 
targeted and cancer-relevant mir n a s include mir16; 
mir21; mir34a, b, and c; mir29b; mir221/222; 
and the 17 to approximately 92 cluster of mir n a s 
individually—and the list is rapidly growing (see 
Stenvang et al. 43 and references therein). Considering 
the role of mir n a s in cancer, the low toxicity of l n a  
in primates, and the feasibility of efficient targeting 
of mir n a s in vivo, the potential impact of this strategy 
is immense.
5.  CHALLENGES
By far the most important challenge faced by re-
searchers developing therapeutic strategies based 
on r n a i is the means to deliver the sir n a s, mir n a s, 
or analogs to the correct cells in the organism. 
Intrinsically, r n a s are polar and labile, and their 
pharmacokinetic properties are completely alien to 
most of the desired cellular destinations. The stabil-
ity of the r n a  molecule can be greatly enhanced by 
blocking the 2′-hydroxy group of ribonucleotides 
and modifying the phosphodiester backbone, but 
delivery must be tailored and optimized for each 
tissue and cellular target. A few early reports de-
scribing direct delivery of naked, unmodified r n a  
molecules to the target tissue appeared success-
ful, one case being sir n a s targeting respiratory 
syncytial virus to the lung 44. In addition, sir n a  
targeting of vascular endothelial growth factors 
α and 1 in age-related macular degeneration has 
been reported 45. However, recent work by Klein-
man et al. called the reasons for these findings into 
question when those authors reported that at least 
some of the anti-angiogenesis virtues of the sir n a  
treatment were independent of its sequence 46. In-
stead, efficacy appeared to depend on the Toll-like 
receptor 3–triggered induction of the interferon γ 
response. That study was seen by some as a set-
back for sir n a-based therapies. For others, it meant 
simply that r n a i- or nucleic acid–based therapy in 
general requires additional fine-tuning to escape 
the innate immune response. Part of the solution 
is likely already underway, because an important 
variety of synthetic material has been established 
and successfully used for sir n a  or nucleic acid de-
livery. The efficient strategies reported range from 
direct conjugation of cholesterol and nucleic acids or 
analogs, to complexation or coating with liposomes 
or polycationic agents. (For a recent and thorough 
review on this topic, see Whitehead et al. 26)
Another important concern for r n a i and mir n a-
based therapy is the unintentional targeting of 
mr n a s, termed “off-targets.” This effect has been 
well characterized using microarray studies of 
sir n a-transfected cells, in which expression in an 
important number of genes declined with increased 
concentration of sir n a s 47,48. It is also thought that 
ectopic expression of mir n a s can result in a related 
effect. Selective pressure normally disfavours the 
presence of sequences complementary to a mir n a  
“seed” in non-targets and co-expressed mr n a s—a 
phenomenon termed “avoidance” 49. Ectopically 
expressed or overexpressed mir n a s in therapy can 
therefore potentially find sequences that are avoided 
under physiologic conditions.
In part, the delivery and off-target issues of 
sir n a- and mir n a-based therapies are linked. Ide-
ally, the means to deliver these nucleic acids, or their 
analogs, to cells would proceed so efficiently as to 
maintain low administered concentrations. More 
efficient delivery should reduce the number of cells 
exposed, favour uptake, and reduce the potential 
for off-target effects, hence maintaining a suitable 
therapeutic index.
6.  CONCLUSIONS
Although the field of r n a i is still an emerging one, 
the benefits of understanding the roles of mir n a s and 
sir n a s in cancer are potentially enormous, not only 
for their roles as cancer loci, but also because for the 
growing likelihood that small r n a s can be used as 
therapeutics in treating cancer itself 30.
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